Cold Plasma Market worth $3.03 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global cold plasma market will grow from $2.15 billion in 2026 to $3.03 billion by 2031, a 7.1% CAGR, supported by adoption in healthcare, semiconductors, electronics, plastics and sustainable manufacturing. Medical applications, particularly wound healing, are forecast to be the fastest-growing segment, while atmospheric cold plasma held a 63.2% market share in 2025. Investment and M&A activity accelerated, including Mycronic's approximately $87.5 million acquisition of Surfx Technologies in 2025 and Niterra Ventures' $18 million investment in Neoplas Med in 2024.

Analysis

This is not a market-moving demand datapoint for NDSN, MYCR, TPE, BOY, or JDG: the addressable pool is small relative to their consolidated revenue bases, and third-party market-sizing forecasts do not establish order conversion. The investable implication is narrower—customers are paying for inline process control and application-specific tooling rather than commodity plasma generators, favoring companies with installed bases, service penetration, and qualification relationships. MYCR and TPE have the clearest semiconductor/upstream manufacturing torque if advanced-packaging and substrate-cleaning capex remains resilient; NDSN has the lowest idiosyncratic exposure but can monetize adjacent dispensing, curing, and surface-preparation workflows.

The more consequential second-order effect is margin mix. Replacing chemical treatments can raise customer switching costs once a process is qualified, supporting recurring consumables, field service, and software/process-control attach rates; however, it also makes revenue highly sensitive to customer fab utilization and automotive/consumer-electronics production rather than to broad ESG spending. For BOY, plasma is a niche technology extension rather than a material earnings driver, while APYX's valuation sensitivity is primarily to aesthetic-procedure adoption and reimbursement/clinical evidence—not industrial surface-treatment growth.

Over the next 1-3 months, treat this as an M&A-screening signal rather than a directional catalyst: subscale private technology vendors could command strategic premiums, but acquirers risk paying for unproven medical commercialization. Over 6-18 months, the key falsifier for the equipment thesis is a deterioration in semiconductor equipment orders or management commentary showing plasma attach rates failing to translate into service revenue and gross-margin expansion. The contrarian view is that the listed incumbents may be too diversified for this theme to alter estimates; the cleaner exposure is private, making broad public-equity rerating unlikely absent disclosed backlog or a material acquisition.

Key Decisions for Investors

• No standalone catalyst trade on the market forecast. Maintain MYCR on an event-driven watchlist; initiate only after the next results show acquired plasma revenue/backlog and semiconductor orders supporting a credible FY revenue contribution. Exit if order intake weakens for two consecutive quarters or acquisition-margin dilution exceeds guidance.
• Relative-value preference: long MYCR / short a broad semiconductor-equipment proxy such as SOXX for a 3-6 month horizon only if MYCR demonstrates plasma-led order acceleration versus peer equipment bookings. Target 10-15% relative upside; stop at 7% relative underperformance, since the thesis depends on company-specific execution rather than sector beta.
• For conservative industrial exposure, retain NDSN rather than adding APYX on this theme. NDSN's plasma adjacency is unlikely to move estimates, but diversification limits downside; APYX requires separate evidence of procedure growth, cash runway, and regulatory/clinical traction before a long is justified.
• Monitor JDG and TPE for bolt-on acquisition announcements or disclosed plasma-system order growth over the next 6-12 months. A deal funded at an elevated multiple without explicit revenue, cross-sell, and margin targets would be a short-term negative, even if strategically coherent.